Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 94-9027 on-demand and prophylaxis trial in severe hemophilia A
NL-OMON45106Phase 2Active, not recruiting
- Sponsor
- Bayer
- Start
- Oct 2012
- Modality
- Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of damoctocog alfa pegol in hemophilia A (4 arms), sponsored by Bayer. Primary endpoint: Total number of bleedings. Started Oct 2012; status: active, not recruiting.
02
Drugs
damoctocog alfa pegol
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NL-OMON45106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45106.